Developmental expression of the major human hepatic CYP3A enzymes
- PMID: 12975492
- DOI: 10.1124/jpet.103.054841
Developmental expression of the major human hepatic CYP3A enzymes
Abstract
The human cytochrome P4503A forms show expression patterns subject to developmental influence. CYP3A7 and CYP3A4 are generally classified as the major fetal and adult liver forms, respectively. However, characterization of CYP3A4, -3A5, and -3A7 developmental expression has historically been confounded by the lack of CYP3A isoform-specific antibodies or marker enzyme activities. Therefore, the objective of this study was to characterize the developmental expression of hepatic CYP3A forms from early gestation to 18 years of age using up to 212 fetal and pediatric liver samples. Based on immunoquantitation, CYP3A5 protein expression was found to be highly variable, generally independent of age, and more frequently observed for African-American individuals. For differentiation of CYP3A4 and -3A7 levels, dehydroepiandrosterone metabolite patterns for expressed CYP3A forms were characterized and used for simultaneous quantitation of protein levels within liver microsome samples. The major metabolite formed by CYP3A4, 7beta-hydroxy-dehydroepiandrosterone, was identified based on cochromatography and mass spectra matching with the authentic standard. Kinetic analysis showed a 34-fold greater intrinsic clearance of 7beta-hydroxy-dehydroepiandrosterone by CYP3A4 versus -3A7, whereas CYP3A7 showed the highest 16alpha-hydroxy-dehydroepiandrosterone intrinsic clearance. Metabolite profiles for the expressed enzymes were fit to a multiple response model and CYP3A4 and -3A7 levels in fetal and pediatric liver microsome samples were calculated. Fetal liver microsomes showed extremely high CYP3A7 levels (311-158 pmol/mg protein) and significant expression through 6 months postnatal age. Low CYP3A4 expression was noted for fetal liver (< or =10 pmol/mg), with mean levels increasing with postnatal age.
Similar articles
-
Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.Eur J Biochem. 1997 Jul 15;247(2):625-34. doi: 10.1111/j.1432-1033.1997.00625.x. Eur J Biochem. 1997. PMID: 9266706
-
Variability of CYP3A7 expression in human fetal liver.J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. doi: 10.1124/jpet.105.086504. Epub 2005 Apr 21. J Pharmacol Exp Ther. 2005. PMID: 15845858
-
Genetic contribution to variable human CYP3A-mediated metabolism.Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. doi: 10.1016/s0169-409x(02)00066-2. Adv Drug Deliv Rev. 2002. PMID: 12406645 Review.
-
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.Drug Metab Dispos. 2002 Aug;30(8):883-91. doi: 10.1124/dmd.30.8.883. Drug Metab Dispos. 2002. PMID: 12124305
-
New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.Drug Discov Today. 2006 May;11(9-10):440-5. doi: 10.1016/j.drudis.2006.03.002. Drug Discov Today. 2006. PMID: 16635807 Review.
Cited by
-
Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants.AAPS J. 2013 Apr;15(2):447-54. doi: 10.1208/s12248-013-9452-z. Epub 2013 Jan 19. AAPS J. 2013. PMID: 23334978 Free PMC article. Review.
-
Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.Clin Pharmacokinet. 2005;44(10):989-1008. doi: 10.2165/00003088-200544100-00001. Clin Pharmacokinet. 2005. PMID: 16176115 Review.
-
Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.Clin Pharmacokinet. 2020 Apr;59(4):501-518. doi: 10.1007/s40262-019-00827-4. Clin Pharmacokinet. 2020. PMID: 31587145 Clinical Trial.
-
Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review.J Steroid Biochem Mol Biol. 2019 Nov;194:105439. doi: 10.1016/j.jsbmb.2019.105439. Epub 2019 Jul 27. J Steroid Biochem Mol Biol. 2019. PMID: 31362062 Free PMC article. Review.
-
Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.Eur J Pediatr. 2015 Apr;174(4):509-18. doi: 10.1007/s00431-014-2416-1. Epub 2014 Sep 25. Eur J Pediatr. 2015. PMID: 25248340 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources